Logo image of NYXH

NYXOAH SA (NYXH) Stock Fundamental Analysis

NASDAQ:NYXH - Nasdaq - BE0974358906 - Common Stock - Currency: USD

7.42  -0.08 (-1.07%)

After market: 7.89 +0.47 (+6.33%)

Fundamental Rating

3

Taking everything into account, NYXH scores 3 out of 10 in our fundamental rating. NYXH was compared to 187 industry peers in the Health Care Equipment & Supplies industry. NYXH scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NYXH is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NYXH has reported negative net income.
In the past year NYXH has reported a negative cash flow from operations.
NYXH had negative earnings in each of the past 5 years.
NYXH had a negative operating cash flow in each of the past 5 years.
NYXH Yearly Net Income VS EBIT VS OCF VS FCFNYXH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

NYXH has a worse Return On Assets (-51.30%) than 66.84% of its industry peers.
NYXH's Return On Equity of -75.09% is in line compared to the rest of the industry. NYXH outperforms 40.11% of its industry peers.
Industry RankSector Rank
ROA -51.3%
ROE -75.09%
ROIC N/A
ROA(3y)-31.19%
ROA(5y)-24.1%
ROE(3y)-40.78%
ROE(5y)-30.7%
ROIC(3y)N/A
ROIC(5y)N/A
NYXH Yearly ROA, ROE, ROICNYXH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

Looking at the Gross Margin, with a value of 65.54%, NYXH is in the better half of the industry, outperforming 68.98% of the companies in the same industry.
In the last couple of years the Gross Margin of NYXH has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for NYXH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 65.54%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.63%
GM growth 5YN/A
NYXH Yearly Profit, Operating, Gross MarginsNYXH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

4

2. Health

2.1 Basic Checks

NYXH does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NYXH has been increased compared to 1 year ago.
NYXH has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, NYXH has a worse debt to assets ratio.
NYXH Yearly Shares OutstandingNYXH Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
NYXH Yearly Total Debt VS Total AssetsNYXH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -0.12, we must say that NYXH is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -0.12, NYXH perfoms like the industry average, outperforming 43.32% of the companies in the same industry.
A Debt/Equity ratio of 0.22 indicates that NYXH is not too dependend on debt financing.
NYXH has a Debt to Equity ratio of 0.22. This is comparable to the rest of the industry: NYXH outperforms 52.41% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF N/A
Altman-Z -0.12
ROIC/WACCN/A
WACC7.4%
NYXH Yearly LT Debt VS Equity VS FCFNYXH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

NYXH has a Current Ratio of 3.59. This indicates that NYXH is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.59, NYXH is in the better half of the industry, outperforming 63.64% of the companies in the same industry.
A Quick Ratio of 3.35 indicates that NYXH has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.35, NYXH is in the better half of the industry, outperforming 67.38% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.59
Quick Ratio 3.35
NYXH Yearly Current Assets VS Current LiabilitesNYXH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for NYXH have decreased strongly by -31.63% in the last year.
The Revenue for NYXH has decreased by -14.90% in the past year. This is quite bad
Measured over the past years, NYXH shows a very strong growth in Revenue. The Revenue has been growing by 74.42% on average per year.
EPS 1Y (TTM)-31.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-44.1%
Revenue 1Y (TTM)-14.9%
Revenue growth 3Y74.42%
Revenue growth 5YN/A
Sales Q2Q%-12.86%

3.2 Future

Based on estimates for the next years, NYXH will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.61% on average per year.
Based on estimates for the next years, NYXH will show a very strong growth in Revenue. The Revenue will grow by 135.57% on average per year.
EPS Next Y-3.82%
EPS Next 2Y5.42%
EPS Next 3Y10.61%
EPS Next 5YN/A
Revenue Next Year161.55%
Revenue Next 2Y189.02%
Revenue Next 3Y156.85%
Revenue Next 5Y135.57%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NYXH Yearly Revenue VS EstimatesNYXH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
NYXH Yearly EPS VS EstimatesNYXH Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NYXH. In the last year negative earnings were reported.
Also next year NYXH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NYXH Price Earnings VS Forward Price EarningsNYXH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NYXH Per share dataNYXH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.42%
EPS Next 3Y10.61%

More info and screens

0

5. Dividend

5.1 Amount

NYXH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NYXOAH SA

NASDAQ:NYXH (8/8/2025, 8:00:02 PM)

After market: 7.89 +0.47 (+6.33%)

7.42

-0.08 (-1.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-14 2025-05-14/bmo
Earnings (Next)08-18 2025-08-18
Inst Owners25.49%
Inst Owner Change-3.34%
Ins Owners22.07%
Ins Owner ChangeN/A
Market Cap277.73M
Analysts81.43
Price Target14.87 (100.4%)
Short Float %0.56%
Short Ratio1.79
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-10.03%
Min EPS beat(2)-22.16%
Max EPS beat(2)2.11%
EPS beat(4)2
Avg EPS beat(4)-5.72%
Min EPS beat(4)-22.16%
Max EPS beat(4)2.11%
EPS beat(8)5
Avg EPS beat(8)1.43%
EPS beat(12)7
Avg EPS beat(12)-4.08%
EPS beat(16)8
Avg EPS beat(16)-5.04%
Revenue beat(2)0
Avg Revenue beat(2)-37.56%
Min Revenue beat(2)-38.43%
Max Revenue beat(2)-36.69%
Revenue beat(4)0
Avg Revenue beat(4)-35.28%
Min Revenue beat(4)-55.92%
Max Revenue beat(4)-10.09%
Revenue beat(8)1
Avg Revenue beat(8)-22.43%
Revenue beat(12)1
Avg Revenue beat(12)-33.85%
Revenue beat(16)2
Avg Revenue beat(16)-35.91%
PT rev (1m)1.84%
PT rev (3m)3.58%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-17.83%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-0.07%
Revenue NQ rev (3m)-52.28%
Revenue NY rev (1m)-26.91%
Revenue NY rev (3m)-30.19%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 54.66
P/FCF N/A
P/OCF N/A
P/B 2.57
P/tB 5.7
EV/EBITDA N/A
EPS(TTM)-2.31
EYN/A
EPS(NY)-1.86
Fwd EYN/A
FCF(TTM)-1.76
FCFYN/A
OCF(TTM)-1.73
OCFYN/A
SpS0.14
BVpS2.89
TBVpS1.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -51.3%
ROE -75.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 65.54%
FCFM N/A
ROA(3y)-31.19%
ROA(5y)-24.1%
ROE(3y)-40.78%
ROE(5y)-30.7%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.63%
GM growth 5YN/A
F-Score2
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 38.9%
Cap/Sales 25.69%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.59
Quick Ratio 3.35
Altman-Z -0.12
F-Score2
WACC7.4%
ROIC/WACCN/A
Cap/Depr(3y)64.88%
Cap/Depr(5y)74.74%
Cap/Sales(3y)37.33%
Cap/Sales(5y)219.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-31.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-44.1%
EPS Next Y-3.82%
EPS Next 2Y5.42%
EPS Next 3Y10.61%
EPS Next 5YN/A
Revenue 1Y (TTM)-14.9%
Revenue growth 3Y74.42%
Revenue growth 5YN/A
Sales Q2Q%-12.86%
Revenue Next Year161.55%
Revenue Next 2Y189.02%
Revenue Next 3Y156.85%
Revenue Next 5Y135.57%
EBIT growth 1Y-46.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-20.8%
EBIT Next 3Y1.88%
EBIT Next 5Y11.04%
FCF growth 1Y-61.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-63.47%
OCF growth 3YN/A
OCF growth 5YN/A